TRACON Pharmaceuticals (NASDAQ:TCON) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON) in a report issued on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

TRACON Pharmaceuticals Stock Down 26.0 %

NASDAQ TCON opened at $0.03 on Friday. TRACON Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $14.75. The business has a 50 day moving average price of $0.05 and a 200-day moving average price of $0.35. The company has a market cap of $109,802.00, a price-to-earnings ratio of 0.01 and a beta of 1.37.

About TRACON Pharmaceuticals

TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.